262 related articles for article (PubMed ID: 25611245)
21. p40 exhibits better specificity than p63 in distinguishing primary skin adnexal carcinomas from cutaneous metastases.
Lee JJ; Mochel MC; Piris A; Boussahmain C; Mahalingam M; Hoang MP
Hum Pathol; 2014 May; 45(5):1078-83. PubMed ID: 24746214
[TBL] [Abstract][Full Text] [Related]
22. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases.
Lionti S; La Rocca L; Nunnari CM; Barresi V
Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951
[TBL] [Abstract][Full Text] [Related]
23. Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma.
Pryma C; Villamil C; Gibb EA; Oo HZ; Seiler R; Contreras-Sanz A; Douglas J; Black PC; Wang G
Virchows Arch; 2022 Sep; 481(3):397-403. PubMed ID: 35612672
[TBL] [Abstract][Full Text] [Related]
24. Distinct Uroplakin II Staining Pattern in Apocrine Breast Carcinoma.
van Pel DM; Pors J; Yuen E; Chan R; Kos Z; Hayes MM; Wang G
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):681-686. PubMed ID: 36227121
[TBL] [Abstract][Full Text] [Related]
25. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
Gordetsky J; Epstein JI
Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
[TBL] [Abstract][Full Text] [Related]
26. An immunohistochemical analysis of a newly developed, mouse monoclonal p40 (BC28) antibody in lung, bladder, skin, breast, prostate, and head and neck cancers.
Tacha D; Bremer R; Haas T; Qi W
Arch Pathol Lab Med; 2014 Oct; 138(10):1358-64. PubMed ID: 24528495
[TBL] [Abstract][Full Text] [Related]
27. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Antibodies to Detect Uroplakin in Urothelial Carcinomas.
Kristoffersen HL; Røge R; Nielsen S
Appl Immunohistochem Mol Morphol; 2022 May-Jun 01; 30(5):326-332. PubMed ID: 35510771
[TBL] [Abstract][Full Text] [Related]
29. Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma.
Copp HL; Chin JL; Conaway M; Theodorescu D
Cancer; 2006 Jul; 107(1):60-6. PubMed ID: 16691580
[TBL] [Abstract][Full Text] [Related]
30. GATA3 immunohistochemical expression in invasive urothelial carcinoma.
Mohammed KH; Siddiqui MT; Cohen C
Urol Oncol; 2016 Oct; 34(10):432.e9-432.e13. PubMed ID: 27241168
[TBL] [Abstract][Full Text] [Related]
31. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder.
Fatima N; Osunkoya AO
Hum Pathol; 2014 Aug; 45(8):1625-9. PubMed ID: 24824028
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas.
Liu H; Shi J; Wilkerson ML; Lin F
Am J Clin Pathol; 2012 Jul; 138(1):57-64. PubMed ID: 22706858
[TBL] [Abstract][Full Text] [Related]
33. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.
Zhao L; Antic T; Witten D; Paner GP; Taxy JB; Husain A; Gwin K; Mirza MK; Lingen MW; Tretiakova MS
Am J Surg Pathol; 2013 Dec; 37(12):1876-81. PubMed ID: 24121175
[TBL] [Abstract][Full Text] [Related]
34. GATA3 Positivity in Benign Radiated Prostate Glands: A Potential Diagnostic Pitfall.
Wobker SE; Khararjian A; Epstein JI
Am J Surg Pathol; 2017 Apr; 41(4):557-563. PubMed ID: 28291125
[TBL] [Abstract][Full Text] [Related]
35. Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall.
Mirsadraei L; Hodkoff A; Jones K; Shabaik A; Kader AK; Saenz CC; Montironi R; Tacha DE; Fadare O; Hansel DE
Arch Pathol Lab Med; 2018 Feb; 142(2):168-177. PubMed ID: 28795841
[TBL] [Abstract][Full Text] [Related]
36. TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.
Wang X; Lopez-Beltran A; Osunkoya AO; Wang M; Zhang S; Davidson DD; Emerson RE; Williamson SR; Tan PH; Kaimakliotis HZ; Baldridge LA; MacLennan GT; Montironi R; Cheng L
Future Oncol; 2017 Apr; 13(8):705-714. PubMed ID: 28052688
[TBL] [Abstract][Full Text] [Related]
37. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.
Davis DG; Siddiqui MT; Oprea-Ilies G; Stevens K; Osunkoya AO; Cohen C; Li XB
Hum Pathol; 2016 Jan; 47(1):26-31. PubMed ID: 26527523
[TBL] [Abstract][Full Text] [Related]
38. Urothelial tumors with villous morphology: Histomorphology and role of immunohistochemistry in diagnosis.
Mitra S; Chatterjee D; Das A; Gupta K; Radotra BD; Mandal AK
APMIS; 2018 Mar; 126(3):191-200. PubMed ID: 29399882
[TBL] [Abstract][Full Text] [Related]
39. Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma.
Tran L; Mattsson JS; Nodin B; Jönsson P; Planck M; Jirström K; Botling J; Micke P; Brunnström H
Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):648-659. PubMed ID: 26447895
[TBL] [Abstract][Full Text] [Related]
40. Do HOXB13 and P63 have a role in differentiating poorly differentiated prostatic carcinoma from urothelial high-grade carcinoma?
Alshenawy HA; Saied E
APMIS; 2015 Sep; 123(9):772-8. PubMed ID: 26200506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
